569.SIVicplas International Ltd
The schedule
- Fri20Nov
Post-earnings, management's Annual General Meeting will force a confrontation regarding the company's highly leveraged balance sheet and ongoing capex commitments.
- Sun31Jan
- Thu25Mar
First half 2027 results will reveal if the initial heavy scale-up costs in the medical device segment have been fully digested, allowing operating leverage to finally materialize.
- Sun2May
- Sun1Aug
- Sun31Oct
Past
- Fri25Sep
Actual outcome: Bear · $0.07 at outcome
The stock closed at $0.07, below the bear floor of $0.05, indicating a bearish outcome. The earnings release showed a miss on revenue and EPS, with weak guidance signaling continued margin pressure and limited growth prospects. Despite the lack of specific positive developments, the stock fell materially, aligning with the bear case as investors reacted to the disappointing results and cautious outlook.
Vicplas is projected to release full-year FY2026 results. The central debate for this micro-cap is whether the massive 131% YoY top-line revenue expansion can begin reversing the steep plunge into unprofitability.